Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study

• DOI: 10.3389/fonc.2024.1391828
• Publication Date: 2024-07-08T07:56:30Z
• Authors: Shujing Shen; Xingya Li; Sanxing Guo; Liang Xu; Ningning Yan
• Keywords: Clinical endpoint; Progression-free survival

Introduction This retrospective study evaluates the efficacy of camrelizumab combined with anlotinib versus chemotherapy in patients extensive-stage small-cell lung cancer (ES-SCLC) undergoing second-line treatment. Methods Data were sourced from medical records at a Chinese facility, involving 34 diagnosed ES-SCLC after failing first-line Patients divided into two groups: one received (200 mg every 3 weeks) (12 daily for 14 days followed by 7-day rest), while other group physician-chosen administered weeks. The primary endpoint was progression-free survival (PFS), secondary endpoints including overall (OS), objective response rate (ORR), and disease control (DCR). Results combination therapy showed significant improvement PFS compared to (median PFS: 7 months vs. months; hazard ratio (HR): 0.34; 95% confidence interval (CI): 0.15-0.77; p<0.001). However, there no statistically difference OS between groups (16.3 17.3 p=0.82). ORR 52.9% 23.5% (p=0.08), DCR 82.4% 58.8% (p=0.26). Grade or higher adverse events observed 17.6% 29.4% group. Conclusions findings suggest that offers superior anti-tumor manageable safety profile setting patients. regimen may be viable option